On Monday, for the second time in as many business days, Illumina (NASDAQ: ILMN) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% lower, during a session when the S&P 500 (SNPINDEX: ^GSPC) landed in the black with a 0.7% increase.
The move is to sell now, says bank
That morning, Barclays changed its recommendation on Illumina stock to underweight (read: sell) from the previous equal weight (hold). It also pulled the lever on a significant price target decrease, lowering its fair value assessment to $100 per share. Formerly, the bank had tagged the biotech as being worth $130.
Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »
According to reports, Barclays' analysts were concerned that the current U.S./China trade dispute would negatively affect the company's operations. Early last week, the Chinese government put it on its "unreliable entity" list of mistrusted foreign companies. The two countries haven't fully settled their differences, so the situation might linger, to Illumina's likely disadvantage.
Compounding that, last Thursday, Illumina published its fourth-quarter and full-year results. These revealed continued erosion in annual revenue, while top-line guidance for the entirety of 2025 fell short of the consensus analyst estimate.
An overreaction to discouraging news
Illumina will continue to be under something of a cloud while it's on the China blacklist. Other than that, investors were overreacting somewhat to the fourth-quarter and 2024 figures -- the company flipped impressively into the black on the bottom line (compared to the same quarter last year), and it has a solid business in the growing field of genetic sequencing.
Should you invest $1,000 in Illumina right now?
Before you buy stock in Illumina, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Illumina wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $795,728!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of February 7, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Barclays Plc and Illumina. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
